Endurant Capital Management’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-71,640
| Closed | -$1.78M | – | 57 |
|
|
2022
Q2 | $1.78M | Buy |
71,640
+11,908
| +20% | +$295K | 0.62% | 33 |
|
|
2022
Q1 | $2.32M | Buy |
59,732
+22,407
| +60% | +$869K | 0.61% | 35 |
|
|
2021
Q4 | $2.18M | Buy |
+37,325
| New | +$2.18M | 0.53% | 36 |
|
|
2021
Q3 | – | Sell |
-51,031
| Closed | -$4.43M | – | 54 |
|
|
2021
Q2 | $4.43M | Buy |
51,031
+37,599
| +280% | +$3.26M | 1.22% | 32 |
|
|
2021
Q1 | $1.11M | Sell |
13,432
-53,153
| -80% | -$4.38M | 0.29% | 54 |
|
|
2020
Q4 | $6.06M | Buy |
66,585
+10,375
| +18% | +$943K | 2.18% | 15 |
|
|
2020
Q3 | $2.25M | Sell |
56,210
-4,682
| -8% | -$187K | 0.66% | 37 |
|
|
2020
Q2 | $2.09M | Buy |
60,892
+20,160
| +49% | +$692K | 0.11% | 38 |
|
|
2020
Q1 | $905K | Sell |
40,732
-94,290
| -70% | -$2.09M | 0.41% | 37 |
|
|
2019
Q4 | $2.64M | Sell |
135,022
-31,760
| -19% | -$621K | 0.83% | 30 |
|
|
2019
Q3 | $2.59M | Buy |
+166,782
| New | +$2.59M | 0.93% | 23 |
|
|
2018
Q4 | – | Sell |
-204,333
| Closed | -$3.33M | – | 61 |
|
|
2018
Q3 | $3.33M | Buy |
204,333
+121,761
| +147% | +$1.98M | 1.48% | 26 |
|
|
2018
Q2 | $936K | Sell |
82,572
-72,772
| -47% | -$825K | 0.41% | 46 |
|
|
2018
Q1 | $1.52M | Sell |
155,344
-401,335
| -72% | -$3.92M | 0.57% | 43 |
|
|
2017
Q4 | $3.4M | Buy |
556,679
+283,979
| +104% | +$1.73M | 1.04% | 37 |
|
|
2017
Q3 | $1.08M | Buy |
+272,700
| New | +$1.08M | 0.33% | 66 |
|